IMMX
Immix Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$576.64M
P/E Ratio
—
EPS
$-0.92
Beta
0.12
52W High
$11.61
52W Low
$1.94
50-Day MA
$9.24
200-Day MA
$6.13
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-35.78M |
| Operating Margin | 0.00% |
| Return on Equity | -74.50% |
| Return on Assets | -39.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.59 |
| Price-to-Book | 6.83 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.19M |
| Float | $40.34M |
| % Insiders | 17.56% |
| % Institutions | 45.15% |
Historical Volatility
HV 10-Day
67.00%
HV 20-Day
60.13%
HV 30-Day
66.25%
HV 60-Day
70.77%
HV Rank
4.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($18.46 target)
2
Strong Buy2
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026